Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.42 |
| ▸ | LDHA | P00338 | 1/20 | 0.36 |
| ▸ | SRR | Q9GZT4 | 1/20 | 0.36 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3439292 | 1.00 | SLC22A6 (0.42) | SLC22A6LDHASRRGABRR1LMNA | |
| SCHEMBL1136022 | 1.00 | SLC22A6 (0.42) | SLC22A6LDHASRRGABRR1LMNA | |
| SCHEMBL1405707 | 0.79 | — | — | |
| SCHEMBL30972500 | 0.79 | — | — | |
| SCHEMBL2687087 | 0.79 | — | — | |
| SCHEMBL374298 | 0.79 | — | — | |
| SCHEMBL14212308 | 0.79 | KDM4E (0.38) | TSHRCA1CA2CA9 | |
| SCHEMBL4669398 | 0.78 | SLC22A6 (0.43) | SLC22A6LDHASRRGABRR1LMNA | |
| SCHEMBL1135942 | 0.78 | SLC22A6 (0.43) | SLC22A6LDHASRRGABRR1LMNA | |
| Bicarbonate SCHEMBL17054410 | 0.77 | SLC22A6 (0.63) | SLC22A6GABRR1LMNATSHRCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114875081-A | Green industrial production method of rosuvastatin key intermediate | 湖北迅达药业股份有限公司 | 2022-08-09 | — | — | CN | claimed |
| CN-114410599-A | Carbonyl reductase mutant and application thereof in preparing rosuvastatin chiral intermediate | 浙江工业大学 | 2022-04-29 | — | — | CN | claimed |
| CN-108486075-B | Recombinant carbonyl reductase mutant, gene, engineering bacterium and application thereof | 浙江工业大学 | 2020-11-13 | — | — | CN | claimed |
| WO-2014203045-A1 | A NOVEL, GREEN AND COST EFFECTIVE PROCESS FOR SYNTHESIS OF TERT-BUTYL (3R,5S)-6-OXO-3,5-DIHYDROXY-3,5-O-ISOPROPYLIDENE-HEXANOATE | LUPIN LIMITED (IN) | 2014-12-24 | — | — | WO | claimed |
| US-20120323005-A1 | Process For The Preparation Of Amide Intermediates And Their Use Thereof | MSN LABORATORIES PRIVATE LIMITED (IN) | 2012-12-20 | — | — | US | claimed |
| WO-2011086584-A2 | IMPROVED PROCESS FOR THE PREPARATION OF AMIDE INTERMEDIATES AND THEIR USE THEREOF | MSN LABORATORIES LIMITED (IN) | 2011-07-21 | — | — | WO | claimed |
| CN-101432435-A | Method for the enantioselective enzymatic reduction of hydroxyketo compounds | IEP GMBH (DE) | 2009-05-13 | — | — | CN | claimed |
| EP-1152054-B1 | NOVEL CARBONYL REDUCTASE, GENE THEREOF AND METHOD OF USING THE SAME | KANEKA CORP (JP) | 2005-03-23 | — | — | EP | claimed |
| US-6645746-B1 | Expression vector; transformants; E. coli; Candida; Bacillus; use of microorganisms to produce t-butyl(3R,5S)-6-chloro-3,5 -dihydroxyhexanoate, by enzymatic asymmetrical reduction, for drug, pesticide and HMG-CoA reductase inhibitor synthesis | KANEKA CORPORATION (JP) | 2003-11-11 | — | — | US | claimed |
| EP-1152054-A1 | NOVEL CARBONYL REDUCTASE, GENE THEREOF AND METHOD OF USING THE SAME | Kaneka Corporation (JP) | 2001-11-07 | — | — | EP | claimed |
| CN-117904066-A | Recombinant carbonyl reductase mutant and application thereof in catalytic synthesis of chiral alcohol | 浙江工业大学 | 2024-04-19 | — | — | CN | disclosed |
| CN-117625707-A | Biological preparation method of (2S, 4R) -4-hydroxytetrahydrofuran-2-tert-butyl acetate | 苏州华道生物药业股份有限公司 | 2024-03-01 | — | — | CN | disclosed |
| CN-117326977-A | Preparation method of 6-cyano-5-hydroxy-3-oxo caproate | 浙江财和生物科技有限公司 | 2024-01-02 | — | — | CN | disclosed |
| CN-114410599-B | Carbonyl reductase mutant and application thereof in preparation of rosuvastatin chiral intermediate | 浙江工业大学 | 2023-08-18 | — | — | CN | disclosed |
| CN-114875081-A | Green industrial production method of rosuvastatin key intermediate | 湖北迅达药业股份有限公司 | 2022-08-09 | — | — | CN | disclosed |
| EP-1152054-A1 | NOVEL CARBONYL REDUCTASE, GENE THEREOF AND METHOD OF USING THE SAME | Kaneka Corporation (JP) | 2001-11-07 | — | — | EP | disclosed |
| WO-2001040450-A1 | NOVEL CARBONYL REDUCTASE, GENE THEREOF AND METHOD OF USING THE SAME | KANEKA CORPORATION (JP) | 2001-06-07 | — | — | WO | disclosed |
| US-5594153-A | REACTING 6-HALO-3,5-DIHYDROXYHEXANOIC ACID OR DERIVATIVE THEREOF WITH DIETHER, KETONE OR UNSATURATED ETHER TO FORM 1,3-DIOXANE DERIVATIVE | E. R. SQUIBB & SONS, INC. (US) | 1997-01-14 | — | — | US | disclosed |
| US-5457227-A | Condensing halo-substituted hydroxy ester with acetic acid, acetate salt or ester in presence of condensation agent to produce halo-substituted hydroxy keto ester | E. R. SQUIBB & SONS, INC. (US) | 1995-10-10 | — | — | US | disclosed |
| US-5278313-A | Chemical condensation reaction | E. R. SQUIBB & SONS, INC. (US) | 1994-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120323005-A1 | Process For The Preparation Of Amide Intermediates And Their Use Thereof | CETP, LCAT, APOB | SLC22A6 3213/4885LDHA 2332/4885SRR 385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.